In June 2010, the taxane anticancer drug cabazitaxel (Jevtana; Sanofi–Aventis), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with hormone-refractory metastatic prostate cancer who had been previously treated with a regimen containing the taxane docetaxel.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties
European Journal of Medical Research Open Access 30 January 2024
-
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Genome Medicine Open Access 21 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).
Higano, C. S. et al. Sipuleucel-T. Nature Rev. Drug Discov. 9, 513–514 (2010).
Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253–265 (2004).
Mita, A. C. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15, 723–730 (2009).
Pivot, X. et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19, 1547–1552 (2008).
US Food and Drug Administration. FDA labelling information — Jevtana (cabazitaxel). FDA website [online], (2010).
De Bono, J. S. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J. Clin. Oncol. 28 (Suppl. 15), 4508 (2010).
Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447–4454 (2008).
Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407–6415 (2008).
Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496–1501 (2010).
Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489–1495 (2010).
Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375, 1437–1446 (2010).
Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
IMS MIDAS (IMS Health, 2010).
Hauber, A. et al. JP Morgan Europe Research (JP Morgan Cazenove, 21 May 2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
W.K.O has received research funding from Sanofi-Aventis and Genentech, and has acted as a consultant for Amgen, Centocor, Genentech and Bellicum.
Rights and permissions
About this article
Cite this article
Galsky, M., Dritselis, A., Kirkpatrick, P. et al. Cabazitaxel. Nat Rev Drug Discov 9, 677–678 (2010). https://doi.org/10.1038/nrd3254
Issue Date:
DOI: https://doi.org/10.1038/nrd3254
This article is cited by
-
Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties
European Journal of Medical Research (2024)
-
Facile preparation of cabazitaxel-loaded nanoparticles directly lyophilized from dioxane
Science China Materials (2023)
-
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
Clinical Reviews in Allergy & Immunology (2022)
-
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Genome Medicine (2021)
-
Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies
Journal of Molecular Modeling (2020)